NFE2L2 and cancer: Based on the evidence that the antioxidant transcription factor NF-E2-related factor 2 (Nrf2) is constitutively activated in CSCs, it is appreciated that Nrf2-mediated cytoprotective responses contribute to the resistance of CSCs to therapeutic agent-induced ROS insults, the arsenal for cancer treatment [12,13,14,15].